Introduction
============

Normal cellular metabolism results in the continual production of reactive oxygen species (ROS). However, exposure to xenobiotics, ionising and nonionsing radiation etc. may lead to an increased production that overwhelms the antioxidant defences, leading to a condition of oxidative stress. Even normal levels of ROS production leads to modification of cellular biomolecules, such as DNA, lipids and proteins, for the most part, without detrimental effects upon the cell. However, under oxidative stress, levels of modification increase and this may have implications for cellular function.

Perhaps most studied, is oxidative modification of DNA, and whilst the principle consequence of this might be mutations, it should not be forgotten that ROS-induced damage to DNA may have non-mutational effects, such as the acceleration of telomere shortening \[[@B1]\]. Over 30 nucleobase modifications have been described, of which 8-oxo-7,8-dihydroguanine (8-oxoGua, and its corresponding deoxyribonucleoside equivalent, 8-oxo-7,8-dihydro-2\'-deoxyguanosine, 8-oxodG; Fig. [1](#F1){ref-type="fig"}), have received the greatest amount of attention \[[@B2]\], although the total number of DNA lesions (including sugar and phosphate modifications, and combinations thereof) is approaching 70 \[[@B3]\]. DNA may also be modified via reactive intermediates, arising from the interaction of ROS with lipids and proteins, leading to adducts such as 1,*N*^6^-etheno-2\'-deoxyadenosine (εdA), 3-(2-deoxy-β-D-*erythro*-pentofuranosyl)pyrimido\[1,2-α\]purin-10(3*H*)-one (M~1~dG) and DNA-protein cross-links \[[@B4]\].

There is a rapidly growing body evidence which suggests that this plethora of lesions, arising from oxidative stress, may have an important role in the aetiology and/or pathogenesis of many diseases, such as cancer and aging (reviewed in Cooke *et al.* \[[@B5]\]). To fully understand the extent to which such DNA lesions are involved in disease, in order to develop diagnostic/prognostic methods and intervention strategies, methods for their analysis are essential. A wide variety of approaches have been employed to study oxidatively damaged DNA. However, findings from the European Standards Committee on Oxidative DNA Damage (ESCODD \[[@B6]\]), have suggested that a number of these techniques suffer from artefactual oxidation during sample workup and analysis (reviewed by Guetens *et al.* \[[@B7]\]). Of relevance to all the above techniques is the possibility of adventitious oxidation during sample storage and, with the exception of the cell-based methods, DNA extraction, although methods have been developed to minimise this risk \[[@B8]\].

Assessment of damage to DNA by methods requiring invasive procedures, e.g. blood samples or tissue biopsy, imposes severe limitations in large-scale human studies, requiring staff with specialist training, greater ethical scrutiny, and reducing the likelihood of consent. In constrast, examining the products of oxidatively generated damage to DNA in extracellular matrices offers a means by which oxidative stress may be assessed non-, or minimally, invasively, and circumvents DNA extraction and associated risk of artefact.

Methods of Analysis
===================

Broadly, methods that have been applied to the study of oxidatively damaged DNA lesions in urine are either chromatographic \[principally, HPLC-MS/MS; liquid chromatography pre-purification prior to GC-MS (i.e. HPLC-GC/MS), HPLC-EC, GC-MS\], or immunoassay. Whilst a variety of lesions have been reported to be present in urine (Table [1](#T1){ref-type="table"}), the majority of assays focus upon 8-oxodG as the analyte of choice, in part, for reasons that will be discussed later.

Chromatographic techniques
--------------------------

Whilst thymine (and thymidine) glycol was one of the first ROS-induced DNA lesions to be studied in urine \[[@B9], [@B10]\], this was rapidly superceded by 8-oxodG, given the one thousand-fold greater sensitivity of 8-oxodG detection using HPLC-EC, compared to the UV detection of Tg, along with the predominance of 8-oxodG over Tg, in human urine \[[@B11]\]. A number of methods based upon column-switching HPLC with regular reverse phase (usually C18) separative columns and EC-detection for assay of 8-oxodG have been developed \[[@B6], [@B12]--[@B14]\]. An approach shown to be successful in a wide variety of biological matrices (including DNA, urine, plasma, red blood cell extracts, cerebrospinal fluid, saliva, sweat, kidney dialysate, brain and muscle microdialysate, food (rat, mouse, monkey and human chow), *Caenorhabitbditis elegans*, cell culture medium and rat faeces), utilises an HPLC column comprising 'treated' carbon material, similar to that used for EC detector cells, together with Coularray, multichannel electrochemical detection \[[@B15]\].

At its simplest, column switching has meant that, following chromatographic separation of the urine's constituents, only the fraction containing the compound of interest (e.g. 8-oxodG) is applied to the final separation column and detector, either EC \[[@B16], [@B17]\] or MS \[[@B18]\]; the remainder is diverted to waste. Benefits of mass spectrometry include: the use of isotopically-labelled internal standards, simplifying quantification and accounting for loss during sample workup (and potentially storage), differences in ionisation efficiencies due to matrix effects, and confirmation of analyte identity. The HPLC-MS/MS assay described by Weimann *et al.* \[[@B18]\] was the first report for the simultaneous analysis of the oxidised (8-oxoGua, 8-oxoguanosine and 8-oxodG) and native (Gua, guanosine and dG) moieties. Similarly, the HPLC-GC/MS assay of Olinski's laboratory entails HPLC pre-purification of the compounds of interest, which again includes native compounds; 8-oxoGua, 8-oxodG, Gua, dG and 5-(hydroxymethyl)uracil (5-HMUra), \[[@B19], [@B20]\], prior to derivatisation and GC-MS. Other urinary, oxidatively modified DNA (2\'-deoxy)nucleobase products measured in urine include 5-hydroxyuracil (5-OHUra), 8-oxo-7,8-dihydroadenine (8-oxoAde) \[[@B21]\], 5-hydroxymethyl-2\'-deoxyuridine (5-OHmUrd) \[[@B22]\], M~1~dG \[[@B23]\], εdA \[[@B24]\] and 3,*N*^4^-etheno-2\'-deoxycytidine (εdC) \[[@B25]\].

Solid phase extraction (SPE) has been used for the analysis of urinary 8-oxodG by GC-MS \[[@B26]\] and HPLC-MS/MS, the latter of which minimised the incidence of interfering peaks reported by Lin *et al.* \[[@B26]\] in 10--20% of their urine samples \[[@B27]\]. The analysis of urinary 8-oxodA has been attempted previously \[[@B28]\], but levels were reported to be at, or below, the limit of detection for the HPLC-MS/MS assay (0.3 nM, 7.5 fmol injected, S/N = 3). A similar finding was noted with an SPE-based HPLC-MS/MS assay \[[@B29]\].

Whilst not as prevalent as methods for analysing primary DNA products of oxidation in urine, the analysis of secondary DNA products of oxidation reactions in urine is a rapidly growing area of interest. Several methods have been developed for the measurement of lipid peroxidation-induced etheno-DNA adducts in human urine. For example, HPLC-fluorescence detection of εdA \[[@B30]\]; isotope dilution-gas chromatography-negative ion chemical ionization/mass spectrometry methodology for 3,*N*^4^-ethenocytosine (εCyt) and 3,*N*^4^-ethenodeoxycytidine (εdC) \[[@B31], [@B32]\]; HPLC MS/MS analysis of urinary εdA \[[@B24]\] and εdC \[[@B33]\] and a ^32^P-postlabeling method has been reported for εdC in human urine \[[@B25]\].

Although not presently used for urinary analysis of DNA oxidation products, accelerator mass spectrometry (AMS) is an emerging technology for measuring radiocarbon-labeled nucleotides and nucleosides \[[@B34]--[@B38]\]. For radiocarbon, AMS has attomole sensitivity for DNA samples as small as a microgram. This technology is currently used with HPLC to measure pharmacokinetics and metabolism of xenobiotics \[[@B39]--[@B42]\] and, more recently, 8-oxodG metabolism \[[@B36]\].

Immunoassay
-----------

Competitive enzyme-linked immunosorbent assay (ELISA) has received widespread, and growing, use for the analysis of lesions in extracellular matrices. Predominantly, 8-oxodG has been the lesion of choice for commercially available (e.g. from the Japanese Institute for the Control of Aging, JaICA), and custom made \[[@B43]\] ELISAs. The benefits of ELISA are (i) ease of use; (ii) no specialist (or indeed expensive) equipment is required; (iii) potential application to numerous extracellular matrices (serum \[[@B44]\], plasma \[[@B45]\], saliva \[[@B46], [@B47]\], urine \[[@B48]\], CSF \[[@B49], [@B50]\], cell culture medium \[[@B51]--[@B53]\] and sputum \[[@B54]\]; (iv) other than centrifugation of cloudy specimens, no pre-treatment of urine is required (v) high throughput. The kit from JaICA has, by far, received the most published use.

Sources of Extracellular, Oxidatively-Modified DNA Lesions
==========================================================

The possible sources of extracellular, oxidatively-modified, DNA lesions are: (i) DNA repair, (ii) diet, (iii) cell death/turnover, mitochondrial turnover and, most recently added to this list, (iv) cellular uptake and re-utilisation of damage products.

DNA repair
----------

The DNA N-glycosylases responsible for removing modified bases are increasingly well defined \[[@B2], [@B55]\]. The prevailing thought is that quantitatively, BER is by far the most important route for the removal of the majority of oxidatively-derived lesions. At its simplest, this process involves a specific enzyme, with a defined repertoire of substrate, removing the modified base, leaving an apurinic-apyrimidinic (AP) site. The subsequent fate of this AP site is proposed to be dependent upon whether the glycosylase also possesses an AP lyase activity, and may involve simply the removal of one nucleotide (short patch repair), or 2--6 nucleotides (long patch repair), followed by gap filling and ligation \[[@B56]\].

The glycosylase considered to have the primary activity in removing 8-oxoGua in human cells, is the human 8-oxoGua glycosylase 1 (hOGG1 \[[@B57], [@B58]\]). This enzyme acts via short patch repair, and has a specificity for 8-oxoGua:Cyt pairs present in double-stranded DNA, i.e. formed in situ (Fig. [2](#F2){ref-type="fig"}). The activity of hOGG1 is complemented by another enzyme, denoted hOGG2, which appears to have similarities to prokaryotic endonuclease VII (Nei) enzymes. It has been reported that hOGG2, removes the 8-oxoGua from the nascent strand in 8-oxoGua:Ade or 8-oxoGua:Gua pairs, arising from misincorporation of 8-OH-dGTP (REF 50). Subsequent studies of eukaryotic NEI-like glycosylases (NEIL) suggest that while these enzymes, NEIL1 and NEIL2, can act on single stranded DNA and thus may have functions in DNA replication/transcription, OGG2 is possibly distinct from NEIL1 and NEIL2 on the basis of size and/or substrate specificity. However, it still would appaear that neither the protein nor the gene for OGG2 has been squenced, or formally identified as an existing, characterised, enzyme. Certainly 8-oxoGua appears to be a substrate for glycosylases other than OGG1 (NEIL1, NEIL2, NTH1) in various contexts, for example in single-stranded DNA, proximal to a 3\'-end, or mispaired with Gua \[[@B59], [@B60]\] (Fig. [2](#F2){ref-type="fig"}).

The contribution of OGG1 enzyme to levels of urinary 8-oxoGua has been examined in *OGG1* −/− mice, which showed a 26% reduction in the deficient strain, compared to wild type, indicating that, in mice at least, OGG1 is a significant, but by no means unique, source of urinary 8-oxoGua \[[@B61]\]. The results clearly support the existence of back up DNA glycosylase(s), such as the Nei-like glycosylases \[[@B62]\], but which cannot entirely compensate for OGG1 deficiency.

In contrast, the presence of 2\'-deoxyribonucleoside lesions in extracellular matrices is less well-defined, not least as there are no reports of a single DNA repair enzyme whose activity yields 8-oxodG. Based upon existing evidence, we suggest the following DNA repair routes (Fig. [2](#F2){ref-type="fig"}) as likely contributors to the presence of oxidatively-modified 2\'-deoxyribonucleosides in urine:

### Nudix hydrolases

Free deoxynucleotides have a greater propensity for oxidation compared to base-paired deoxynucleotides in DNA \[[@B63]\]. Furthermore, mitochondrial sources of dNTPs are larger than nuclear sources (*mitochondria*: 18.0 pmol dGTP/µg DNA versus *nuclear*: 8.0 pmol dGTP/µg DNA \[[@B64]\]). Taken together, these would suggest an imperative for preventing modified DNA precursors being incorporated into the genome. The best characterised enzyme which performs such a role is the 8-oxo-2\'-deoxyguanosine triphosphatase (8-oxodGTPase \[[@B65]\]) activity of NUDT1 (aka MutT homologue, MTH1), hydrolysing 8-oxodGTP to 8-oxodGMP (Fig. [2](#F2){ref-type="fig"}). It has been suggested that further processing, perhaps by 5\'(3\')-nucleotidases, may give rise to 8-oxodG \[[@B65]\], which can be removed from the cell to ultimately appear in the urine. Recent data from the group of Harms-Ringdahl strongly imply that NUDT1 activity, and thus the nucleotide pool, represents a major source of extracellular 8-oxodG \[[@B66]\]. However, the roles of other Nudix hydrolases such as NUDT15 (MTH2) and NUDT5, which include 8-oxodGTP and 8-oxodGDP amongst their substrate repertoire respectively, remain to be defined \[[@B67], [@B68]\].

### Nucleotide excision repair (NER)

Principally, NER removes bulky lesions, such as cyclobutane thymine dimers (T\<\>T), although there is there is some evidence for activity towards 8-oxodG (Fig. [2](#F2){ref-type="fig"}) \[[@B69]\]. Indeed, the rate of 8-oxoGua removal appears comparable to that for T\<\>T \[69\], the implication being that a lesion-containing oligomer, approximately 24--32 nucleotides long is then produced \[[@B70]\]. Galloway *et al.* \[[@B71]\] showed that, post-excision, T\<\>T-containing oligomers are subsequently degraded to lesion-containing 7-mers. What then happens to the oligomers is unknown, although, from the findings of Le Curieux and Hemminki \[[@B72]\], who detected the presence of urinary T\<\>T as a monophosphate nucleotide dimer, it may be implied that further processing does occur, the nature of which remains to be described. The situation for 8-oxodG is even less clear as a recent report failed to demonstrate 8-oxoGua-containing oligomers in urine \[[@B73]\] implying that further processing occurs, perhaps ultimately yielding 8-oxodG, or that they do not exist. However, under normal circumstances, when BER and NER are allowed to compete, NER appears to have a negligible role in the removal of 8-oxoGua \[[@B74]--[@B78]\]. Eliminating Ogg1 activity (*Ogg1*^−/−^ mice) while reducing 8-oxoGua excretion by 26%, has no impact on the excretion of 8-oxodG compared to wild-type animals \[[@B61]\]. This perhaps suggests that other BER activities compensate for lost OGG1 activity, or if NER is contributing, it is either minimal even under these circumstances or 8-oxoGua-containing oligomers are not subject to further degradation. Results from experiments with XP cell lines have not entirely excluded the possibility of a role for NER in the repair of 8-oxoGua, however some XP proteins are also thought to play a role in BER, through modulating OGG1 activity, for example \[[@B69], [@B75], [@B79]--[@B81]\].

### Nucleotide Incision Repair (NIR)

This is a more recently described DNA repair pathway whose lesion repertoire is more oriented towards oxidised pyrimidines, rather than purines. However, dependent on the structural context, 8-oxoGua can be a substrate, when 8-oxo-Gua is present at the 3\'-end of a DNA strand break, such a situation could occur from mis-incorporation of 8-oxodGMP during DNA synthesis or damage induced by ionising radiation, in this context 8-oxoGua is reistant to excision by OGG1. The 3\'-5\' exonuclease activity of Apn1, in *S. cerevisiae*, and APE-1, in humans, has been demostrated to fulfill this NIR activity towards 8-oxoGua in such a context \[[@B82], [@B83]\]. An important issue with this pathway is that the initial product of NIR is a lesion-containing 2\'-deoxyribonucleoside 3\'-monophosphate, which could then be a substrate for a 5\'(3\')-nucleotidase activity, to yield 8-oxodG.

### Mismatch Repair (MMR)

The recognition of mis-incorporated 8-oxoGua either opposite G or A can render the lesion a substrate for MMR \[[@B84], [@B85]\]. Recognition of the mispair by MutSα and MutLα heterodimeric complexes ultimately invokes a long-patch repair process in which exonuclease I, targeted to the nascent strand, sequentially removes 2\'-deoxynucleotide monophosphates in the 5\'-3\' direction, again gnerating a lesion-containing that could be further degraded 8-oxodG by a 5\'(3\')-nucleotidase activity.

### Endonuclease(s)

A poorly characterised endonuclease has been reported by Bessho *et al.* \[[@B86]\] which, lacking a glycosylase activity, is predicted to give rise to 3\',5\'-8-oxodGDP as the putative product. We have previously proposed that this may be subsequently hydrolysed to 8-oxodG by nucleotidase(s).

As noted earlier, in addition to 8-oxodG, the following modified 2\'-deoxyribonucleosides have been identified in urine: dTg, 5-OHmUrd, M~1~dG, εdA, and εdC, and their origins are even less clear.

Potential confounders
---------------------

### Diet

The majority of reports measuring oxidatively modified DNA lesions in urine, have focussed upon 2\'-deoxyribonucleoside lesions, and 8-oxodG specifically. The reason for this is because early work in the field demonstrated that diet could affect levels of urinary 8-oxoGua, but not 8-oxodG. Whilst it was concluded that Tg was unaffected by diet, the raw data would suggest otherwise: gastric intubation of rats demonstrated that 44% of ingested \[^3^H\]-Tg was recovered intact in the urine within 24 h (\[[@B87]\] and discussed in detail by Cooke *et al.* \[[@B88]\]). It is worth noting that the results from the HPLC-based assay used in the Park *et al.* \[[@B89]\] paper, examining urinary 8-oxoGua and 8-oxodG are perhaps questionable, as the assay utilised a monoclonal antibody which was not entirely specific for 8-oxodG. There would appear to be little human data on the subject of dietary contribution, not all of which agree with the animal findings. Gackowski *et al.* \[[@B90]\] have suggested that, in humans, neither 8-oxoGua, nor 8-oxodG, are affected by diet. However, pivotal to this study was the assumption that, like rats \[[@B89]\], humans reach a minimum level of 8-oxoGua excretion 2--3 days after switching to a nucleic acid-free diet. Similarly, it was assumed that a maximum level of 8-oxoGua excretion was reached 3--5 days after reverting to a normal diet. Additional sampling points throughout this study would make these conclusions more definitive.

In contrast, there is agreement between all studies showing that urinary 2\'-deoxynucleoside lesions, are unaffected by diet. In rats, this was demonstrated by both the nucleic acid-free diet studies and intubation studies (only 1% of \[^3^H\]-8-oxodG and 5% of \[^3^H\]- thymidine glycol, dTg, appeared in the urine; \[[@B91]\] and \[[@B87]\], respectively). Cathcart *et al.* \[[@B87]\] suggest that the low levels of radioactivity probably derive from faecal contamination of the urine samples, the true values being closer to zero. In humans, the results of Gackowski \[[@B90]\], described above, concur with the studies in rats.

For completeness, it is worth considering ribonucleoside lesions, although there have been very few reports examining oxidatively-modified ribonucleosides in urine \[[@B18], [@B92]\]. Such studies may be justified by reports which suggest a negligible contribution from diet to urinary modified ribonucleoside levels \[[@B93], [@B94]\]. However, there are also data that indicate diet influences urinary levels of 8-oxoGuo, in rats at least (nucleic acid-free diet excreted 908 +/− 357 pmol of 8-oxoG/kg/day, compared to 2810 +/− 830 pmol of 8-oxodGuo/kg/day for those fed normal chow \[[@B89]\].

Urinary levels of another lesion, N^2^-methyl-8-oxo-7,8-dihydroguanine, have been measured and noted to be elevated in ill and growing infants, initially suggesting a role for this oxidatively-modified tRNA component as a marker of oxidative stress \[[@B95]\]. However, its apparent absence in tRNA and reduction in urinary levels following administration of allopurinol, would suggest its production and appearance in urine is due to the action of xanthine dehydrogenase/oxidase, clearly ruling out its use as a biomarker of tRNA oxidation \[[@B95]\]. In contrast, 8-oxoGuo and 8-oxodG excretion was unaffected by administration of allopurinol \[[@B95]\], as was 8-oxoGua excretion (Helbock *et al.* unpublished results, refered to in \[95\]), further supporting the compounds are biomarkers of oxidatively generated damage.

Whilst oxidative modification of DNA bases, such as 8-oxoGua, may have a number of detrimental consequences for the cell \[[@B1]\], including mutation \[[@B2]\], the significance of oxidatively modified ribonucleosides is not so well defined \[[@B1]\], but may be associated with abnormal protein translation and defects in protein synthesis \[[@B96]--[@B98]\]. It is concluded that the source, and certainly the significance, of oxidatively modified ribonucleosides in urine is even less clear than for nucleobases and 2\'-deoxyribonucleosides, particularly as some oxidised ribonucleosides may be products of cellular synthesis and may be considered endogenous. Further studies, preferably in humans, examining the source and significance of extracellular, oxidatively-modified ribonucleosides are clearly warranted. This is all the more important in the light of recent work describing the role of Y-box binding protein 1 and polynucleotide phosphorylase \[[@B99]\] in sequestering 8-oxoGua-containing transcripts (the possibility of RNA 'repair' is considered in greater detail in Evans and Cooke \[[@B1]\]) coupled with the observations that oxidised mRNA induces trnaslational errors \[[@B100]\].

Recent human studies investigating dietary contribution
-------------------------------------------------------

Upon ingestion, nucleic acids are rapidly fragmented, by mastication combined with enzymic digestion and acid hydrolysis in the buccal cavity and gastro-intestinal tract (GIT \[[@B101]\]). Enzymes which can catalyse hydrolysis include DNase I, from salivary glands, the pancreas, liver and Paneth cells of the small intestine, may be present in high concentrations, combined with DNase II, whose optimal pH (4.6--5.5) makes it particularly suited to activity in the upper GIT \[[@B101]\]. The low pH of the stomach may allow depurination of DNA, generating free adenine and guanine, as *in vitro* studies have shown \[[@B102]\], although it is not clear whether this is the case for 8-oxodG, as the *N*-glycosidic bond appears to be very chemically stable \[[@B103]\].

Even though specific transport systems are reported to exist for bases and nucleosides, for healthy, well-nourished individuals, reliance on dietary sources of nucleosides to supplement salvage and *de novo* synthesis is negligible \[[@B104]\]. Furthermore, even in those tissues that do apparently utilise dietary sources of nucleosides to supplement endogenous nucleotide synthesis, e.g. bone marrow and intestine, the contribution from diet is still regarded as minimal. Enterocytes may absorb some dietary nucleosides, but in the case of dietary purine nucleosides significant catabolism in the proximal small intestine results in complete degradation of these species to uric acid \[[@B105], [@B106]\], this is in contrast to pyrimidines which do show some incorporation in cellular nucleic acids \[[@B107]\]. Collectively, it would appear unlikely that diet contributes to the levels of oxidatively-modified purines in urine, although the case for pyrimidine lesions may not be quite as clear. Nevertheless, a definitive exclusion of dietary contribution, is still required, and may have to be explored on a lesion-by-lesion basis.

Studies utilising radio-labelled lesions are preferred over those involving nucleic acid-free diets as the use of radiolabels provides a degree of stringency not afforded by nucleic acid-free diets (possible short-comings of nucleic acid-free diets have been discussed above). For example, the presence of labelled lesions in the urine/faeces, cross-contamination notwithstanding, can only come from the dietary source. However, for ethical reasons, radio-labelled lesions are to be avoided in human studies. To circumvent this issue, Cooke *et al.* \[[@B20]\] reported a feeding study using heavily damaged, stable isotopically-labelled \[^15^N\]-DNA (98% incorporation) and discussed thoroughly the fate of ingested DNA. The \[^15^N\]-DNA, had been irradiated with a dose of 50 kJ/m^2^ UVC shown, by a previous study, to induce approximately 600 8-oxodG/10^5^ dG \[[@B108]\].

Healthy, male volunteers were fed 5, 15 or 25 mg of the damaged \[^15^N\]-DNA, and first void, mid-stream urine samples were collected for up to 14 days later. The presence of \[^15^N~5~\]-8-oxodG, and \[^15^N~5~\]-8-oxoGua in urine was investigated using HPLC-GC/MS \[[@B90]\]. Neither lesion was detected in any of the urine samples. To confirm that the absence of lesion was not a sensitivity issue, urinary \[^15^N~5~\]-dG and \[^15^N~5~\]-Gua, which should be present at significant levels, was also examined. Again, neither of these labelled compounds were detected in any of the urine samples. The authors also investigated whether any of the ingested \[^15^N~5~\]-Gua/dG had been degraded to \[^15^N~5~\]-uric acid, the final product of purine metabolism, prior to excretion, again, no labelled material was detected.

Unlike previous studies, which had only been performed in animals, the authors also examined the DNA from peripheral blood mononuclear cells (PBMC), collected for up to seven days following ingestion of labelled DNA, for possible incorporation of label. The justification for this derived from reports that phage DNA may appear in a diverse range of cell types, including PBMC, 24 h after ingestion by mice \[[@B109], [@B110]\], implying that a proportion of DNA consumed is not entirely degraded, and may be both absorbed and integrated. The relevance of such findings to plant and animal DNA has been questioned \[[@B101]\]. Yet again, no \[^15^N~5~\]-labelled Gua, or \[^15^N~5~\]-8-oxoGua, was detected in the PBMC DNA. This result is consistent with previous findings, in mice and chickens, that dietary purines, are not incorporated into cellular nucleic acids \[[@B107]\]. No information on pyrimidine components was presented.

As with previous studies \[[@B111]\], Cooke *et al.* \[[@B20]\] could only presume that the isotopically labelled DNA components/adducts pass through the gastro-intestinal tract to appear in faeces. Nevertheless, these results, coupled with the findings of Gackowski *et al.* \[[@B90]\], provide the most compelling argument that diet is not a significant contributor to both urinary 8-oxoGua and 8-oxodG levels in human urine. This is consistent with the animal data relating to 2\'-deoxyribonucleoside lesions \[[@B111]\], which includes dTg \[[@B87]\], but disagrees with early data for 8-oxoGua and Tg \[[@B87], [@B112]\]. Species differences may be proposed to account for this discrepancy, although the focus of our attention must be upon the more relevant, human data. Earlier animal studies should be repeated using the highly specific and sensitive mass spectrometric techniques.

### Cell death/turnover

It has been stated that urinary 8-oxodG does not reflect DNA repair, as it is not a product of base excision repair \[[@B113]\], rather it was a product of non-specific nucleases, acting upon DNA released during cell death, liberating dG which is subsequently oxidised (or indeed free 8-oxodG itself). Such a hypothesis did not leave scope for the potential existence of other, as yet undiscovered, repair pathways, which may yield 8-oxodG, and in any case, oxidation of dG in the systemic circulations does not appear to occur (discussed below, under Issues of artefact and stability). Whilst repair processes, whose reaction product may be 8-oxodG, have subsequently been described (see above), the possible contribution from cell turnover remains to be addressed. Indeed, most of the evidence against a contribution from cell turnover is anecdotal. For example, there exists a number of reports in which urinary 8-oxodG has been measured in patients undergoing chemotherapy, in which cytotoxic agents are used to cause (cancer) cell death. No increases in urinary 8-oxodG were noted in the studies of both Faure *et al.* \[[@B114]\] and Erhola *et al.* \[[@B115]\], despite evidence of extensive cell death i.e. significant increases (*p*\<0.01) in urinary uric acid (a biochemical index of cell turnover); and reduction in tumour mass. Furthermore any reported increases in urinary 8-oxodG following chemo- or radiotherapy have been attributed entirely to DNA repair \[[@B116], [@B117]\]. Thus far, the most decisive argument against the contribution of cell death to urinary levels of 8-oxodG and 8-oxoGua comes from a report from the Olinski group \[[@B118]\]. This study revealed that a statistically significant (*p* = 0.0003) increase (60%) in 8-oxoGua was observed 24 h after infusion of the cisplatin, a period when no loss of blood cells was reported. In the "nadir days", when the most distinct cell death can be observed, urinary excretion of 8-oxoGua dropped significantly in comparison with the aforementioned time point. The implication being that cell death does not appear to contribute to urinary 8-oxoGua (and 8-oxodG) in humans.

Is there any evidence to suggest that 8-oxodG may be liberated from DNA whilst in the systemic circulation? Perhaps. It has been reported that rat liver homogenates can release 8-oxodG from oxidatively-modified DNA \[[@B119]\]. The authors suggest that, during DNA degradation, most of the 8-oxodG, present in DNA, is released by enzymes, and subsequently appears in the urine, implying this to be a major source. However, they do acknowledge their system does not accurately represent the *in vivo* situation, not least as it is unrealistic---multiple, uncompartmentalised nucleases acting upon circulating DNA, particularly as the majority of cell death in healthy humans will be via apoptosis.

It has been suggested by Cooke *et al.* \[[@B120]\] that were cell death to be the primary source of urinary lesions, the ratio between native and modified, in urine, would be similar to that seen in cells (reportedly anywhere between one 8-oxodG/10^5^ and one 8-oxodG/10^7^ dG \[[@B121]\], although the recommendation from ESCODD is that the level in lymphocytes is likely to be somewhere between 4.2 and 0.3 8-oxodG per 10^6^ dG \[[@B8]\]. In fact the ratio appears to be very close. For the 2\'-deoxyribonucleoside: 28 (+/− 2) 8-oxodG: 12 (+/− 2) dG nmol/24 h, although not as close for the nucleobase: 136 +/− 12 8-oxoGua: 1931 (+/− 182) Gua nmol/24 h \[[@B18]\]. Neither ratio even approaches that seen in cells. Of course, were dG or Gua to be metabolised upon release from DNA, as reported by Shi *et al.* \[[@B119]\], this could account for the closeness of the ratio. Indeed this suggestion might be supported by the findings of Bialkowski *et al.* \[[@B103]\], who noted that the *N*-glycosidic bond is more stable for 8-oxodG, than dG. Nevertheless,Weimann *et al.* \[[@B73]\], in a study examining oligonucleotides in urine, concluded that the limited excretion of oligonucleotides into urine argues against oligonucleotides, or indeed nucleosides, originating from cell death \[[@B73]\]. On balance, these results suggest that the contribution of cell death to urinary 8-oxodG levels is minimal, but clearly further work needs to be performed.

### Uptake and re-utilisation

In contrast to 8-oxoG in DNA, little information is available on the mutagenic potential and cellular responses to the presence of free 8-oxodG. The cellular metabolism of 8-oxodG is the subject of an emerging and sometimes conflicting literature. In human cells, dG predominantly undergoes phosphorolysis by purine nucleoside phosphorylase (PNP) to form the free nucleobase Gua and 2\'-deoxyribose-1\'-phosphate. The resulting free nucleobase is a substrate for hypoxanthine-guanine phosphoribosyltransferase (HGPRT), resulting in formation of GMP. Two additional phosphorylation steps afford GTP, which serves as a substrate for RNA polymerase-dependent incorporation into RNA. This pathway can also feed into DNA synthesis, since GDP can be reduced to dGDP by ribonucleotide reductase (RR) by replacement of the 2\'-OH with a hydrogen atom. This pathway is represented schematically by:

dG→Gua→GMP→GDP→GTP→RNA

and

dG→Gua→GMP→GDP→dGDP→dGTP→DNA

Alternatively, cellular deoxycytidine kinase (dCK) or mitochondrial deoxyguanosine kinase (dGK) phosphorylate dG to form dGMP, which can then be serially phosphorylated to dGTP prior to incorporation into DNA during replication or repair synthesis:

dG→dGMP→dGDP→dGTP→DNA.

Based upon the known nucleotide salvage pathways for dG, 8-oxodG may also be metabolized by two distinct pathways.

\(1\) If 8-oxodG is a substrate for PNP, the nucleobase portion of 8-oxodG can be hydrolyzed from the 2\'-deoxyribose ring. The resulting 8-oxoGua is a substrate for nucleotide salvage, resulting in the ribonucleotide and 2\'-deoxyribonucleotide triphosphates 8-oxoGTP and 8-oxodGTP, respectively, which contribute to RNA and DNA synthesis.

\(2\) Direct mono-, di- and triphosphorylation of 8-oxodG would result in formation of 8-oxodGTP, a substrate for DNA synthesis \[[@B122]--[@B128]\]. Both possible pathways reflect the known metabolism of the canonical 2\'-deoxynucleoside dG described above \[[@B129]--[@B131]\]. However, nucleotide salavage of 8-oxodG is complicated by contributions from BER via OGG1 and OGG2 and nucleotide pool "cleansing" by nudix hydrolases and 5\'-nucleotidase activity as shown in Fig. [3](#F3){ref-type="fig"}.

In an effort to determine whether 8-oxodG is a substrate for the human nucleotide salvage pathways that utilize dG, Henderson and coworkers measured \[^14^C\]8-oxodG metabolism in MCF-7 cells \[[@B35]\]. The \[^14^C\]8-oxodG was labeled on the nucleobase in order to probe both possible nucleotide salvage mechanisms. AMS was required for the study since the levels of ^14^C-labeled metabolites were too low be be detected by other mass spectrometry methods and well below the limit of detection for liquid scintillation counting. The ability of cells dosed with extracellular 8-oxodG to import 8-oxodG and employ either PNP-dependent nucleotide salvage or direct phosphorylation for nucleic acid synthesis was investigated. Incorporation of exogoenous 8-oxodG was observed at a concentration of approximately one 8-oxoG nucleobase per 10^7^ nucleotides in DNA and one 8-oxoG per 10^6^ nucleotides in RNA, in cells exposed to concentrations of 8-oxodG approximating those present in human plasma (\~100 fmol per mL) \[[@B89]\]. Resulting levels of 8-oxoGua incorporated into DNA and RNA, were at concentrations within an order of magnitude of those typically reported for mammalian cells as measured by HPLC-EC \[[@B8]\].

These initial observations were accompanied by inhibitor-based experiments aimed at determining the mechanism of incorporation. The \[^14^C\]8-oxodG experiments were repeated in the presence of inhibitors of PNP, RR and dCK \[[@B132]\]. The inhibition of PNP almost completely abrogated incorporation of radiocarbon into both DNA and RNA, indicating PNP as a gatekeeper of 8-oxodG catabolism. Inhibition of RR resulted in reduced radiocarbon incorporation into DNA, but had little effect on 8-oxoG incorporation into RNA, indicating that 8-oxoGDP is a substrate for RR, which leads to incorporation of the nucleobase portion of the exogenous 8-oxodG into DNA. Inhibition of dCK had no effect on radiocarbon incorporation into DNA and RNA compared to controls with no inhibitor, supporting, at best, a minimal contribution by direct phosphorylation of 8-oxodG to the overall metabolism, which is in contrast to catabolism of dG \[[@B132]\].

An intruiging possible consequence of nucleotide salvage for DNA and nucleotide pool repair pathways is the production of both 8-oxodG and 8-oxoGua that may ultimately be excreted in urine. Prevention of the incorporation of 8-oxodG into DNA or RNA derives from the activity of MTH1 and 5\'-nucleotidase. Whether 8-oxodGMP is a substrate for cellular dGMP nucleotidase activity remains unanswered.

The recently published data on exogenous 8-oxodG is in partial agreement with the literature. For example, Zeng *et al.* \[[@B133]\] demonstrated that HGPRT can catalyse the formation of 8-oxoGuo monophosphate from 8-oxoGua, which is consistent with PNP-dependent nucleotide salvage of 8-oxodG. However, this process has not been specifically demonstrated to occur *in vivo*, even in a cell culture system. The extracellular addition of 400 µM 8-oxodG to a number of leukaemic cell lines (KG-1, H9, CEM-CM3, Molt-4), in which hOGG1 activity is absent or low, results in cytotoxicity and the accumulation of 8-oxoGua in their nuclear DNA \[[@B134], [@B135]\], consistent with PNP-mediated cleavage of the glycosidic bond of 8-oxodG. However, this increase 8-oxoGua does not appear to be due to the direct incorporation of the extracellular 8-oxodG \[[@B136]\]. However, this study reported the use of tritium-labeled 8-oxodG in which the radioactive label resided on the 2\'-deoxyribose ring, which would be precluded from incorporation into DNA unless there was direct phosphorylation by dCK or dGK. It has previously been reported that 8-oxodG is not a substrate for deoxynucleoside kinase \[[@B137]\] or guanylate kinase \[[@B65]\], which are not required by the PNP-mediated pathway for incorporation of 8-oxoGua into DNA or RNA. The report by Kim et al claimed that the 8-oxodG was not substantially degraded to 8-oxoGua, supporting the notion that the fate of 8-oxodG, once present following repair, is excreted, intact, into extracellular compartments \[[@B136]\]. However, we would have to question the biological relevence of using an extracellular concentration of 400 µM 8-oxodG. For example, Henderson and coworkers demonstrated that increasing concentrations of 8-oxodG in the cell culture medium above approximately 2 µM resulted in saturation of nucleotide salvage resulting little or no additional incorporation into DNA with increased 8-oxodG concentrations in the media \[[@B35]\].

Kim *et al.* \[[@B136]\] provided evidence concurring with an earlier report \[[@B65]\] that 8-oxodG is not phosphorylated to 8-oxodGMP. The authors hypothesise that the cytotoxicity of 8-oxodG is, in part at least, via error-prone DNA synthesis, mediated by DNA polymerase β \[[@B136]\], implying that cytosolic 8-oxodG, whilst not a substrate for (re-) incorporation into DNA, may not be as benign as previously thought. Alternative explanation is that very high concentrations, 8-oxodG interferes with feedback inhibited control of dGTP concentrations via PNP-mediated proceses, resulting in toxic levels of dGTP in the cells dosed with 400 µM 8-oxodG.

Issues of artefact and stability
--------------------------------

The potential exists, as for DNA, that urinary lesions may arise from the artefactual oxidation of nucleobases, or 2\'-deoxyribonucleosides, following exposure to metabolic enzymes, or other oxidising species, after release into the systemic circulation, or in the urine. However, Shigenaga *et al.* \[[@B111]\] showed that dG is not artefactually oxidised in the systemic circulation, or following incubation with microsomal enzymes. Equally, 8-oxodG, Tg and dTg are not subject to degradation upon release into the systemic circulation (\[[@B87], [@B111]\], the stability of 8-oxoGua not having been examined. Experimental studies with 8-oxodG injected intravenously have shown that recovery is almost complete in urine in pigs, implying that further metabolism in the systemic circulation is an unlikely event \[[@B138]\].

Furthermore, as significant concentrations of hydrogen peroxide have been reported to be present in urine \[[@B26], [@B139]\]. Lin *et al.* (2004) examined the potential for 8-oxodG to be generated from dG, present in the urine. In a recent study combinations of dG (1 nmol) and hydrogen peroxide (50 or 100 µM), were incubated in a number of urine samples, for 24 h, at room temperature \[[@B26]\]. The authors concluded that hydrogen peroxide has a negligible effect upon 8-oxodG production, under these circumstances, agreeing with previous results from Ames' laboratory. Storage of urine samples at --20°C does not lead to a decrease in urinary 8-oxodG concentrations, when analysed over a 15 year period \[[@B140]\], making urine an ideal matrix to store in biobanks for future analysis.

Whilst the above provide evidence of stability in extracellular matrices, it is worth noting that 8-oxodG is more prone to oxidation than dG, due to its lower redox potential \[[@B141], [@B142]\] and is preferentially oxidised, even in the presence of an excess of Gua \[[@B143], [@B144]\]. By the same token, oxidation of Thy to Tg is less likely to occur, than Gua to 8-oxoGua, due to the lower oxidation potential of Gua, compared to Thy. However, it would appear that most of these studies have examined the oxidation of 8-oxoGua *in situ* in DNA \[[@B145]\], rather than as a post-excision product of DNA repair, which may alter the likelihood of oxidation and its 'oxidisability'. In contrast, M~1~G and M~1~dG both appear to undergo further oxidative metabolism in rat liver cytosol, with the nucleobase adduct being a better substrate for such enzymic oxidation than the deoxyribonucleoside adduct \[[@B146], [@B147]\]. There is also some evidence to suggest that M~1~G is further oxidised when administered intravenously, although M~1~dG was not examined \[[@B146]\].

Overall, it would appear that 8-oxodG, Tg and dTg, and probably 8-oxoGua, are not formed artefactually *in vivo*, in biological matrices of mammals, including humans, and there is no published evidence for their degradation upon release. In contrast, there is strong evidence that M~1~G and M~1~dG may undergo oxidation, either enzymically, or in the systemic circulation.

Conclusions
===========

There is a great deal of evidence, albeit largely circumstantial, implicating a role for oxidatively damaged DNA in various diseases, in particular cancer \[[@B5]\]. Of the biomarkers of oxidatively damaged DNA, urinary 8-oxodG has received perhaps the most interest. The benefits of using urine as a matrix in which to study oxidatively-modified DNA include:

1.  Non-invasive, with ramifications for gaining ethical approval and access to vulnerable groups.

2.  Samples are easily collected (low biological hazard, no pre-processing prior to storage, small volumes), stored (stable at --80°C for \>10 y, with no 'special' treatments or preservatives) and transported.

3.  Stability of 8-oxodG in urine allows access to samples from previous studies/biobanks.

4.  Applicable to the study of large sample size, as many of the assays are semi-automated and with potentially high throughput.

Measurement of this biomarker is also the closest to validation, which includes understanding the provenence of 8-oxodG in urine, evaluation of confounding factors and work towards inter-laboratory consensus. However, an important caveat with validation of urinary biomarkers, is to not simply apply the findings for one lesion, to all the others. For example, we have noted herein that the literature indicates that diet may contribute to levels of urinary 8-oxoGua, but not urinary Tg. To some extent, therefore, all lesions need to be indipendetly validated, drawing on the experience of 8-oxo(d)G.

To accelerate this process, the European Standards Committee of Urinary (DNA) Lesion Analysis (ESCULA) has been formed, which now represents an international group of \>25 laboratories dedicated to the validation of urinary biomarkers of DNA damage (further information, including how to apply for membership, can be found at http://escula.org ).

MSC and MDE are partners of ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: "Food Quality and Safety" (Contract No 513943). PTH was supported by National Institutes of Health Grants RR13461, CA93373, the California Breast Cancer Research Program Grant 9KB-0179 and the Knapp Family Fund.

![Structures of (A) 8-oxo-7,8-dihydroguanine (8-oxoGua), and (B) 8-oxo-7,8-dihydro-2\'-deoxyguanosine (8-oxodG).](jcbnSR09-41f01){#F1}

![DNA repair sources of extracellular 8-oxodG and 8-oxoGua. NER, nucleotide excision repair; hOGG1 and hOGG2, human 8-oxoguanine glycosylase (1 and 2); NIR, nucleotide incision repair; MMR, mis-match repair.](jcbnSR09-41f02){#F2}

![Potential fate of extracellular 8-oxodG, and 8-oxoGua, by metabolic salvage pathways. Neither 8-oxodG, nor 8-oxodGMP can be phosphorylated, as they are not substrates for deoxynucleoside kinase, or guanylate kinase, respectively. Therefore the alternative pathway, discussed by Hah *et al.* \[[@B35]\], relies upon degradation of extracellular 8-oxodG to 8-oxoGua, perhaps by purine nucleoside phosphorylase (PNP). 6-Hydroxypurine phosphoribosyltransferase (HGPRTase) can catalyse the formation of 8-oxoguanosine monophosphate, providing a route for the oxidised moiety, via nucleoside-phosphate kinase (NPK) and nucleoside-diphosphate kinase (NDK), to be incorporated into RNA. In this model ribonucleoside-diphosphate reductase (RDR) is responsible for the conversion of 8-oxoguanine-containing ribonucleotides to deoxyribonucleotide equivalents. Nucleoside-diphosphate kinase then catalyses the phosphorylation of 8-oxodGDP to 8-oxo-7,8-dihydro-2\'-deoxyguanosine triphosphate, a substrate for DNA polymerases for incorporation into DNA. Potential sources of extracellular 8-oxodG and 8-oxoGua are indicated (diet, death, DNA repair) contributions from which may have profound implications for the cell, and our understanding of what measurement of these biomarkers of oxidative stress really means.](jcbnSR09-41f03){#F3}

###### 

DNA-derived markers of oxidative stress examined^1)^ in human urine.

  Nucleobase   Modification                                                                  Abbreviation
  ------------ ----------------------------------------------------------------------------- --------------
  Gua          8-oxo-7,8-dihydroguanine                                                      8-oxoGua
               8-oxo-7,8-dihydro-2\'-deoxyguanosine                                          8-oxodG
               8-oxo-7,8-dihydroguanosine                                                    8-oxoG
               Pyrimido\[1,2-a\]purin-10(3*H*)-one                                           M~1~Gua
               3-(2-deoxy-β-D-*erythro*-pentofuranosyl)pyrimido\[1,2-α\]purin-10(3*H*)-one   M~1~dG
               1, N^2^-ethenoguanine                                                         1, N^2^-εGua
               N^2^-3-ethenoguanine                                                          N^2^-3-εGua
                                                                                             
  Ade          8-oxo-7,8-dihydroadenine                                                      8-oxoAde
               8-oxo-7,8-dihydro-2\'-deoxyadenosine                                          8-oxodA
               1,*N*^6^-etheno-2\'-deoxyadenosine                                            εdA
                                                                                             
  Thy          Thymine glycol                                                                Tg
               Thymidine glycol                                                              dTg
               5-(hydroxymethyl)uracil                                                       5-HMUra
               5-hydroxymethyl-2\'-deoxyuridine                                              5-HMdUrd
               5-hydroxyuracil                                                               5-OHUra
                                                                                             
  Cyt          3,*N*^4^-ethenocytosine                                                       εCyt
               3,*N*^4^-etheno-2\'-deoxycytidine                                             εdC

^1)^ Examined, but not necessarily detected.
